# A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

> **NCT03520491** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 52 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **PROCEDURE:** Radical cystectomy

## Key facts

- **NCT ID:** NCT03520491
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-25
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520491, "A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03520491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*